Appeals court judges’ questions and comments suggested they may be skeptical of Trump administration changes to research ...

The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...

Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time ...

FDA's digital advisors could nudge the agency to clarify how its rules apply to medical applications of generative AI, ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

Healthy people who suffer traumatic spinal injuries are at significantly greater risk for long-term chronic health conditions ...

Danielle Bittterman on finding vulnerabilities in LLMs to make them safer, in this edition of the AI Prognosis newsletter.

CPR can be brutal and ineffective for people clearly at the end of life, but families often insist on it anyway. How should ...

What is "fake" CPR, and why do doctors sometimes do it? STAT's Alex Hogan explains in this week's episode of STATus Report.

Beware of financialization when it is code for “money making money on health,” with no plan for developing the staff, stuff, ...

As Novo Nordisk fights a bidding war against Pfizer to acquire the obesity biotech Metsera, its new CEO dismissed claims that its offer would run into regulatory issues and said that Metsera would ...